Skip to Main Content

A widely anticipated court hearing will be held in India on Wednesday over the cost of a pair of tuberculosis drugs and whether the Indian government will side with activists and sidestep the patents.

At issue are two medicines — Sirutro and Deltyba — that are among the newest treatments for tuberculosis and offer 80% cure rates, which are substantially higher than older medications used for drug-resistant TB and extensively drug-resistant TB. But prices have become a flashpoint, since the medicines are often used in combination with other treatments, which raises the overall costs of treatment even higher.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!